甲磺酸阿帕替尼联合替吉奥对晚期头颈部肿瘤患者的疗效与安全性

Efficacy and Safety of Apatinib Mesylate Combined with Tegafur in the Treatment of Patients with Advanced Head and Neck Tumors

目的分析甲磺酸阿帕替尼联合替吉奥对晚期头颈部肿瘤患者的疗效与安全性。方法回顾性分析40例一线治疗失败的晚期头颈部肿瘤患者,均为武汉科技大学附属天佑医院于2015年10月至2019年10月进行治疗,根据治疗方案的不同分为对照组(n=20,接受替吉奥胶囊治疗)和观察组(n=20,接受替吉奥胶囊联合甲磺酸阿帕替尼治疗)。比较两组患者临床疗效、无进展生存期(PFS)和总生存期、不良反应发生情况。结果两组患者的客观缓解率(ORR)、疾病控制率(DCR)和中位PFS比较,差异无统计学意义(P>0.05)。对照组患者总生存期为3.6~11.2个月,中位总生存期为5.7个月;观察组患者总生存期为6.2~18.4个月,中位总生存期为9.5个月;两组患者中位总生存期比较差异有统计学意义(P<0.05)。两组患者不良反应发生率比较无明显统计学差异(P>0.05)。结论甲磺酸阿帕替尼联合替吉奥对晚期头颈部肿瘤患者有一定的疗效。

Objective To analyze the efficacy and safety of apatinib mesylate combined with tegafur in the treatment of patients with advanced head and neck tumors.Methods A retrospective analysis of 40 patients with advanced head and neck tumors who failed first-line treatment.All were treated from October 2015 to October 2019 in Tianyou Hospital Affiliated to Wuhan University of Science and Technology.They were divided into control groups(n=20,receiving tegafur capsule treatment)and the observation group(n=20,receiving tegafur capsule combined with apatinib mesylate treatment)according to different treatment options.The clinical efficacy,progression-free survival(PFS),overall survival,and occurrence of adverse reactions were compared between the two groups.Results The objective response rate(ORR),disease control rate(DCR)and median PFS of the two groups were not statistically different(P>0.05).The overall survival time of the patients in the control group was 3.6 to 11.2 months,and the median overall survival time was 5.7 months;the overall survival time of the patients in the observation group was 6.2 to 18.4 months,and the median overall survival time was 9.5 months.There was a statistically significant difference in overall survival of two groups(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05).Conclusion Apatinib mesylate combined with tegafur is effective in the treatment of patients with advanced head and neck tumors.